BackgroundMatrix metalloproteinases (MMPs) 2 and 9 may play an important role in cell proliferation and dissemination of cancer. However, few studies have compared the expression of these proteins between breast cancer and fibroadenoma.Material and methodsA randomized, double-blind study was carried out in 66 premenopausal women, aged 20-49 years, who had been diagnosed with fibroadenoma or breast cancer. The patients were divided into two groups: Group A, control (fibroadenoma, n=36) and Group B, study (cancer, n=30). Immunohistochemical analysis was performed using tissue samples of fibroadenoma and breast cancer to assess MMP-2 and MMP-9 antigen expression. Cells were considered positive if exhibiting brown cytoplasmic staining. Fisher’s exact test was used to compare the percentage of cases with cells expressing MMP-2 and MMP-9 in control and study groups (p < 0.05).ResultsLight microscopy showed a higher concentration of cells with positive cytoplasmic staining for MMP-2 and MMP-9 expression in breast cancer than in fibroadenoma. The percentage of cases with cells expressing MMP-2 in the control and study groups was 41.67% and 86.11%, respectively (p < 0.0009), whereas the percentage of cases with cells expressing MMP-9 in groups A and B was 66.67% and 93.33%, respectively (p<0.0138). MMP-2 and MMP-9 positive expression was significantly higher in moderately differentiated tumors compared to well and poorly differentiated tumors, p <0.005 and p<0.001, respectively.ConclusionsThe current study shows that MMP-2 and MMP-9 protein expression was significantly higher in the breast cancer than in the fibroadenoma and also in moderately differentiated breast cancer.

Breast cancer is the most common malignancy affecting women worldwide. The insulin-like growth factor 1 (IGF-1) gene encodes a protein responsible for a wide variety of physiological processes, including differentiation and cell proliferation. Despite several studies on tumor tissues, no study has evaluated IGF-1 expression in the peripheral blood of women with recurrent breast cancer. In this cross-sectional study, IGF-1 expression in the peripheral blood of 146 women with breast cancer treated approximately 5 years ago was quantified by quantitative reverse transcription polymerase chain. The women were divided into 2 groups: non-recurrence (n = 85) and recurrence (n = 61). Statistical analysis of the data was performed using ANOVA, Mann–Whitney, and Chi-squared tests ( P < .05). The results showed no significant difference in IGF-1 expression between the non-recurrence and recurrence groups ( P = .988). In the subgroups of patients with lymph node involvement, no statistically significant difference was observed in IGF-1 expression between women with recurrence and those non-recurrence ( P = .113). In patients without lymph node metastases, IGF-1 messenger ribonucleic acid (mRNA) expression levels were significantly higher in the non-recurrence group than in the recurrence group ( P = .019). Furthermore, using the median IGF-1 mRNA expression as the cutoff point, it was obtained a statistically significant difference in tumor histological grade among women with recurrent breast cancer ( P = .042). These data showed significantly higher IGF-1 expression in women without lymph node metastases in the non-recurrence group compared with the recurrence group. In addition, a significant difference was observed in median IGF-1 mRNA expression in relation to tumor histological grade in women with recurrent breast cancer.

BackgroundGliomas are the most common primary tumors of the central nervous system with unclear etiology, however hereditary factors may play important roles in the development of gliomas with mutations and single nucleotide polymorphisms (SNPs) being prominent among the genetic changes. this systematic review and meta-analysis assess the association of XRCC1 (rs1799782) and ERCC2 (rs13181) gene polymorphisms and glioma risk.MethodsThis study included articles indexed in the PUBMED and EMBASE databases published during the past 15 years. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. The PICOS model was used to develop the inclusion criteria and search terms. This review was recorded at PROSPERO International prospective register of systematic reviews, ID 196173. The META-MAR V2.7.0 meta-analysis calculator was used for the statistical analysis with p-values < 0.05 being considered statistically significant. Dichotomous data are presented as odds ratios (OR) with a 95% confidence interval (CI). Statistical heterogeneity was measured using the I2 test and I2 > 50% were regarded as high heterogeneity. Funnel plots, Begg (BT) and Egger Tests (ET) were used to assess publication bias (p<0.1). Results Literature review identified 10 articles on ERCC2 gene rs13181 variant and 11 on XRCC1 rs1799782. The meta-analysis identified a risk for gliomas for the TT genotype of the XRCC1 rs1799782 SNP in Asians (OR: 1.59, 95% CI: 1.3-1.93; p=0.006; I2 13.1%). ERCC2 rs13181 polymorphisms identified as risks for gliomas were AC genotypes in Asians (OR: 2.06, 95% CI: 1.75-1.42; p = 0.00057; I2 91.1%) and Caucasians (OR: 1.16, 95% CI: 1.01-1.31; p = 0.02; I2 12.2%), and CC genotypes in Caucasians (OR: 2.06, 95% CI: 1.75-1.42; p = 0.0001; I2 98.9%).Conclusions TT genotypes of the XRCC1 rs1799782 SNP in Asians, AC genotypes of ERCC2 rs13181 polymorphisms in Asians and Caucasians, and CC genotypes of ERCC2 rs13181 polymorphisms in Caucasians were associated with increased risk for gliomas that may benefit these patients with early diagnostic and therapeutic strategies.

No abstract